EMA Authorised: Pirfenidone Viatris (Pirfenidone) — Viatris Limited

View source ↗

Summary

EMA authorised Pirfenidone Viatris as a generic version of pirfenidone for idiopathic pulmonary fibrosis in the European Union, expanding access to the IPF indi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease

Drugs mentioned

• Pirfenidone Viatris (pirfenidone)

Snippet

Status: Authorised. Therapeutic area: Idiopathic Pulmonary Fibrosis;Lung Diseases;Respiratory Tract Diseases. MAH: Viatris Limited. Decision date: 18/12/2025